Oslo, Norway, 25 March 2026 - The Board of Directors of Lytix Biopharma AS (the
"Company") (Euronext Growth Oslo: LYTIX) hereby calls for the Annual General
Meeting to be held at Sandakerveien 138, 0484 Oslo, Norway, on 14 April 2026 at
13:00 hours (CEST).
 
The agenda for the Annual General Meeting includes, among other items, approval
of the Company's annual report for 2025, election of board members, approval of
remuneration to the Board of Directors and the Nomination Committee, and a new
board authorization to increase the share capital in connection with the
Company's option program.
 
The Board of Directors proposes that no dividend is distributed for the
financial year 2025.
 
All documents related to the Annual General Meeting, including the notice,
appendices, and the nomination committee's recommendation, are available on the
Company's website: www.lytixbiopharma.com.
 
Shareholders wishing to attend the Annual General Meeting are requested to
register their attendance or submit a proxy by 10 April 2026 at 13:00 (CEST).
 
For further information, please contact:
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Phone: +47 952 60 512

This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.
 
About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company
developing novel immunotherapies based on oncolytic peptides that directly kill
tumor cells and activate the immune system to target solid tumors. The company's
lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic
molecule being evaluated across multiple cancer indications and treatment
settings, both as monotherapy and in combination with immune checkpoint
inhibitors.